Energenesis Biomedical Co., Ltd. (6657) Stock Statistics & Valuation Metrics
Total Valuation
Energenesis Biomedical Co., Ltd. has a market cap or net worth of TWD 2.66B. The enterprise value is TWD 2.53B.
- Market Cap
- TWD 2.66B
- Enterprise Value
- TWD 2.53B
Share Statistics
Energenesis Biomedical Co., Ltd. has 89,749,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 89,749,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Energenesis Biomedical Co., Ltd.’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -30.21%.
- Return on Equity (ROE)
- -0.29
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -30.21%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 219.26K
- Profits Per Employee
- -7.38M
- Employee Count
- 35
- Asset Turnover
- 0.01
- Inventory Turnover
- 2.04
Valuation Ratios
The current PE Ratio of Energenesis Biomedical Co., Ltd. is -9.38. Energenesis Biomedical Co., Ltd.’s PEG ratio is 0.40.
- PE Ratio
- -9.38
- PS Ratio
- 365.90
- PB Ratio
- 3.92
- Price to FCF
- -11.96
- Price to Operating Cash Flow
- -12.13
- PEG Ratio
- 0.40
Income Statement
In the last 12 months, Energenesis Biomedical Co., Ltd. had revenue of 7.67M and earned -258.40M in profits. Earnings per share was -2.92.
- Revenue
- 7.67M
- Gross Profit
- 5.83M
- Operating Income
- -275.27M
- Pretax Income
- -258.40M
- Net Income
- -258.40M
- EBITDA
- -252.70M
- Earnings Per Share (EPS)
- -2.92
Cash Flow
In the last 12 months, operating cash flow was -230.55M and capital expenditures -3.09M, giving a free cash flow of -233.64M billion.
- Operating Cash Flow
- -230.55M
- Free Cash Flow
- -233.64M
- Free Cash Flow per Share
- -2.66
Dividends & Yields
Energenesis Biomedical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.96%
- Earnings Yield
- -11.46%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- -33.03%
- 50-Day Moving Average
- 32.87
- 200-Day Moving Average
- 37.92
- Relative Strength Index (RSI)
- 34.21
- Average Volume (3m)
- 164.00K
Important Dates
Energenesis Biomedical Co., Ltd. upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Energenesis Biomedical Co., Ltd. as a current ratio of 19.91, with Debt / Equity ratio of 1.66%
- Current Ratio
- 19.91
- Quick Ratio
- 19.89
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.60
- Interest Coverage Ratio
- -594.55
Taxes
In the past 12 months, Energenesis Biomedical Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Energenesis Biomedical Co., Ltd. EV to EBITDA ratio is -6.87, with an EV/FCF ratio of -8.78.
- EV to Sales
- 268.43
- EV to EBITDA
- -6.87
- EV to Free Cash Flow
- -8.78
- EV to Operating Cash Flow
- -8.90
Balance Sheet
Energenesis Biomedical Co., Ltd. has TWD 677.38M in cash and marketable securities with TWD 11.74M in debt, giving a net cash position of TWD 665.64M billion.
- Cash & Marketable Securities
- TWD 677.38M
- Total Debt
- TWD 11.74M
- Net Cash
- TWD 665.64M
- Net Cash Per Share
- TWD 7.42
- Tangible Book Value Per Share
- TWD 8.11
Margins
Gross margin is -6.15%, with operating margin of -4108.60%, and net profit margin of -3908.52%.
- Gross Margin
- -6.15%
- Operating Margin
- -4108.60%
- Pretax Margin
- -3908.52%
- Net Profit Margin
- -3908.52%
- EBITDA Margin
- -3905.93%
- EBIT Margin
- -4059.29%
Analyst Forecast
The average price target for Energenesis Biomedical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -4.36%
- EPS Growth Forecast
- 1.97%
